Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.

NCT05293912 is registered in ClinicalTrials.gov with Hangzhou Sumgen Biotech Co., Ltd. as lead sponsor.

NCT NCT05293912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Terminated
Start date
March 3, 2023
Completion date
June 30, 2023
Enrollment
2 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancy, lymphoma